Arvest Bank Trust Division Decreases Stake in AbbVie Inc. $ABBV

Arvest Bank Trust Division cut its stake in shares of AbbVie Inc. (NYSE:ABBV) by 28.8% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 67,645 shares of the company’s stock after selling 27,326 shares during the quarter. Arvest Bank Trust Division’s holdings in AbbVie were worth $15,663,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Cardano Risk Management B.V. lifted its position in shares of AbbVie by 2.4% during the 3rd quarter. Cardano Risk Management B.V. now owns 536,670 shares of the company’s stock valued at $124,260,000 after acquiring an additional 12,629 shares during the period. Wealthcare Advisory Partners LLC raised its holdings in AbbVie by 0.7% during the third quarter. Wealthcare Advisory Partners LLC now owns 46,312 shares of the company’s stock worth $10,723,000 after purchasing an additional 307 shares during the last quarter. Balentine LLC boosted its position in AbbVie by 4.9% during the third quarter. Balentine LLC now owns 5,647 shares of the company’s stock worth $1,307,000 after purchasing an additional 264 shares in the last quarter. Putney Financial Group LLC grew its holdings in AbbVie by 2.1% in the third quarter. Putney Financial Group LLC now owns 4,339 shares of the company’s stock valued at $1,005,000 after purchasing an additional 91 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ increased its position in shares of AbbVie by 7.1% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 947,375 shares of the company’s stock valued at $219,564,000 after buying an additional 62,956 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Trading Up 1.8%

Shares of NYSE:ABBV opened at $231.57 on Tuesday. The firm has a market cap of $409.28 billion, a price-to-earnings ratio of 98.12, a PEG ratio of 0.81 and a beta of 0.35. The stock’s 50-day moving average price is $223.73 and its two-hundred day moving average price is $221.37. AbbVie Inc. has a 12-month low of $164.39 and a 12-month high of $244.81.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company’s revenue was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

ABBV has been the topic of several recent research reports. Raymond James Financial set a $256.00 price objective on shares of AbbVie in a research report on Monday, November 3rd. Evercore reduced their price target on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a report on Wednesday, February 4th. UBS Group lowered their price target on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Morgan Stanley lifted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Finally, Guggenheim increased their target price on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.